Screener
Amphastar Pharmaceuticals AMPH US — Non-Current Assets
Other geography segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Amphastar Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NoncurrentAssets.
The source filing: Amphastar Pharmaceuticals’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:50 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001297184-26-000047
| Line item | Net Revenues / Three Months Ended / June 30, 2026 | Net Revenues / Three Months Ended / June 30, 2025 | Net Revenues / Six Months Ended / June 30, 2026 | Net Revenues / Six Months Ended / June 30, 2025 | Long-Lived Assets / June 30, 2026 | Long-Lived Assets / December 31, 2025 |
|---|---|---|---|---|---|---|
| United States | $172,342 | $167,002 | $331,382 | $329,592 | $247,218 | $206,697 |
| China | 4,560 | 299 | 7,042 | 380 | 107,268 | 110,055 |
| France | 7,001 | 7,113 | 16,650 | 14,970 | 34,640 | 36,967 |
| Total | $183,903 | $174,414 | $355,074 | $344,942 | $389,126 | $353,719 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Amphastar Pharmaceuticals's US — non-current assets?
- Amphastar Pharmaceuticals (AMPH) reported US — non-current assets of $247.22M in Q2 2026.
- How has Amphastar Pharmaceuticals's US — non-current assets changed year-over-year?
- Amphastar Pharmaceuticals's US — non-current assets increased by 19.4% year-over-year, from $207.03M to $247.22M.
- What is the long-term trend for Amphastar Pharmaceuticals's US — non-current assets?
- Over 4 years (2021 to 2025), Amphastar Pharmaceuticals's US — non-current assets has grown at a 11.8% compound annual growth rate (CAGR), from $530.03M to $829.02M.
- What does US — non-current assets mean?
- This metric captures the long-term assets held by the company within its United States operations that are not expected to be converted to cash within a single fiscal year. It includes investments in infrastructure, intellectual property, and long-term capital projects essential for sustaining domestic manufacturing and distribution capabilities. Monitoring this balance helps assess the scale of the company's long-term capital commitment to its domestic business segment.
Ask your AI about Amphastar Pharmaceuticals's us — non-current assets.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude